University Of Zürich

Biogen International Neuroscience Gmbh

Neurimmune Holding Ag

Biogen Idec International Neuroscience Gmbh

Boehringer Ingelheim Pharma Kg

Unversität Zürich

Christoph Hock

Roger Nitsch

Jan Grimm

Paul H Weinreb

Fabio Montrasio

Maria Grazia Barenco Montrasio

Andreas Weihofen

Kathrin Tissot

Christoph Esslinger

Marlen Knobloch

Jean-Luc Baeriswyl

Lihe Su

Marcel Maier

Janaky Coomaraswamy

Omar Quintero-Monzon

Feng Chen

Tobias Welt

Jordan Mcafoose

Marion Wienrich

Klaus Mendla

Andreas Raschig

Klaus Bornemann

Cornelia Dorner-Ciossek

Dieter Horst Meier

Jordan McAfoose

Mario Merlini

Antonella Santuccione Chadha

Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.

Human anti-SOD1 antibodies

Provided are TAR DNA-binding protein of 43 kDa (TDP-43)-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.

TDP-43 specific binding molecules

Provided are novel human &#x3b1;-synuclein-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for &#x3b1;-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for &#x3b1;-synuclein targeted immunotherapy and diagnosis, respectively.

Human anti-alpha-synuclein antibodies

Provided are anti-human &#x3b1;-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human &#x3b1;-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human &#x3b1;-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for &#x3b1;-synuclein targeted immunotherapy and diagnosis, respectively.

Anti-alpha synuclein binding molecules

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

Method of providing disease-specific binding molecules and targets

Methods of treating Alzheimer's disease

Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for &#x3b1;-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for &#x3b1;-synuclein targeted immunotherapy and diagnosis, respectively.

Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.

Human anti-tau antibodies

Provided are novel TAR DNA-binding proteins of 43 kDa ('TDP-43')-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.

Provided are anti-human &#x3b1;-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human &#x3b1;-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human &#x3b1;-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for &#x3b1;-synuclein targeted immunotherapy and diagnosis, respectively.

Anti-&#x3b1; synuclein binding molecules

Growing community of inventors

Erlenbach, Switzerland

Christoph Hock